Lotta Baumgärtel
lottabaumgaertel.bsky.social
Lotta Baumgärtel
@lottabaumgaertel.bsky.social
PhD student in the @SaterialeLab studying Cryptosporidium @TheCrick London, UK.
Reposted by Lotta Baumgärtel
Our paper has finally graduated from pre-print to peer-reviewed, pretty much unscathed, and is out now! www.cell.com/cell/fulltex...
The essential host genome for Cryptosporidium survival exposes metabolic dependencies that can be leveraged for treatment
An arrayed microscopy-based CRISPR screen revealed host genes affecting multiple infection phenotypes of the intracellular parasite Cryptosporidium. Hits in the host cholesterol biosynthesis pathway a...
www.cell.com
July 24, 2025 at 2:08 PM
Reposted by Lotta Baumgärtel
Cryptosporidium modifies intestinal microvilli through an
exported virulence factor!! Phenomenal work from the newly DR’ed Elena Rodrigues
www.biorxiv.org/content/10.1...
Cryptosporidium modifies intestinal microvilli through an exported virulence factor
Cryptosporidium is a common intestinal infection of vertebrates and a significant threat to public health. Within the epithelial layer of the intestine, the parasite invades and replicates. Infected cells are readily detected under the microscope by the presence of elongated microvilli, particularly around the vacuole where the parasite resides. Here, we identify a family of Cryptosporidium virulence factors that are exported into the host cell during infection and localise to the microvilli. We examine the trafficking and function of the most highly expressed family member, MVP1, which appears to control the elongation of microvilli through engagement of host EBP50 and CDC42. Remarkably, this mechanism closely mirrors that of an enteropathogenic Escherichia coli virulence factor, MAP, which is also known to drive host microvilli elongation during infection. This highlights a unique instance where eukaryotic and prokaryotic virulence factors have convergently evolved to modulate host actin structures through a similar mechanism. ### Competing Interest Statement The authors have declared no competing interest.
www.biorxiv.org
February 26, 2025 at 12:53 PM